Pt # | Gender | Histology | Metastatic disease site | Vax # | Clinical response before immunotherapy | Clinical response after immunotherapy | Additional treatment before immunotherapy | Adverse effects (grade) | Survival in months |
---|---|---|---|---|---|---|---|---|---|
01 | F | CC | Liver | 1 | PD | PD | Sunitinib | No | 20 m+ |
02 | M | CC | Lung, bone | 1 | PD | PD | None | No | 20 m+ |
03 | M | CC | Lung, bone | 1 | PD | PR | None | No | 20 m+ |
04 | M | CC | Lung, bone | 2 | PD | SD | None | No | 19 m+ |
05 | M | CC | Lung, Liver | 6 | SD | PR | None | No | 19 m+ |
06 | M | CC | Bone | 4 | PD | SD | None | No | 18 m+ |
07 | M | CC | Bone | 1 | PD | SD | None | No | 17 m+ |
08 | M | CC | Lung | 4 | SD | PR | None | No | 18 m+ |
09 | M | CC | Lung, Liver, Brain | 2 | PD | SD | None | No | 21 m+ |
10 | M | CC | Chest | 3 | PD | SD | None | No | 16 m+ |
11 | M | CC | Lung | 1 | PD | PR | None | No | 16 m+ |
12 | M | CC | Liver | 1 | PD | PD | None | Fever (grade1) | 15 m+ |
13 | M | CC | Neck lymph | 1 | PD | CR | None | No | 10 m+ |
14 | M | CC | Lung | 1 | PD | SD | None | No | 10 m+ |
15 | M | CC | Lung | 3 | PD | PR | None | No | 9 m+ |
16 | M | CC | Lung | 3 | PD | CR | None | No | 10 m+ |
17 | M | CC | Abdominal | 1 | PD | CR | None | No | 15 m+ |
18 | M | CC | Lung | 1 | PD | PD | None | No | 12 m+ |
19 | M | CC | peritoneum lymph | 1 | SD | PR | None | No | 21 m+ |
20 | F | CC | Liver, Bone | 1 | PD | PD | None | No | 15 m+ |
21 | F | CC | Abdominal | 2 | PD | PD | None | No | 16 m+ |
22 | M | CC | Bone | 2 | SD | CR | sorafenib | No | 20 m+ |
23 | M | CC | Lung, Bone | 3 | SD | SD | None | No | 6 m+ |
24 | F | CC | Lung, Bone | 1 | PD | death | None | No | 4 m+ |
25 | M | CC | Lung, Liver | 3 | PD | PR | Sorafenib + Sunitinib | No | 6 m+ |
26 | F | CC | Peritoneum lymph | 2 | SD | SD | None | No | 11 m+ |
27 | M | CC | Lung, Bone | 2 | PD | SD | None | No | 5 m+ |
28 | M | CC | Lung | 2 | SD | SD | sorafenib | No | 5 m+ |